Notice NOT-CA-22-008 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-054 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Funding Opportunity RFA-HD-22-017 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to request applications to develop, adapt, and/or test physical activity interventions for individuals who use wheelchairs due to physical disability. The goal of the proposed interventions should be to safely prevent, or reverse chronic conditions associated with low physical activity such as diabetes, cardiovascular disease, and obesity. Inclusion criteria must be based on functional status rather than the primary condition leading to disability. Interventions that could be applied or easily adapted to large populations of wheelchair users and used in multiple settings are a priority.

Funding Opportunity RFA-AT-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotype participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.

Funding Opportunity RFA-AT-22-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care. The overall goal of this initiative is to support the "real world" assessment of pain management interventions and/or health care strategies to enhance adherence to pain management guidelines in health care systems that may lead to improved SCD pain management, allowing access to opioid pain management when needed. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings, and it is expected that most data will be obtained through the electronic records of the health care system. Trials should be conducted across three or more health care systems (HCS) that provide care to SCD patient populations. Clinical trials will be conducted within the infrastructure of the HEAL Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) Program Coordinating Center, which has dedicated pain, implementation science, and pragmatic clinical trial design. Awarded applicants will work with the Health Care Systems Research Collaboratory Coordinating Center (HCS CCC) (https://rethinkingclinicaltrials.org/) to facilitate further planning and refinement of the proposed study in partnerships with health care delivery systems.

Notice NOT-OD-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-22-004 from the NIH Guide for Grants and Contracts. Specifically, this FOA will be for novel and varied technology development projects to characterize rare cells at single cell level. As such, the review of the FOAs falls outside the mission and scope of any of the existing standing CSR study sections and will require additional expertise and review criteria.

Funding Opportunity RFA-RM-22-005 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

Notice NOT-HS-22-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-002 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support research to identify cell-specific mechanisms in biomolecular condensate (BMC) formation and function, providing novel information for the role BMCs play in diverse cell types in the context of aging and neurobiology of Alzheimers disease (AD) or AD-related dementias (ADRD). This research should enhance our understanding of the cell-specific mechanistic role of BMCs in aging and AD/ADRD and serve as the foundation for more comprehensive etiological studies that might lead to the development of future BMC-based therapies for age-related neurodegenerative diseases.

Notice NOT-OD-22-018 from the NIH Guide for Grants and Contracts

Notice NOT-DC-22-004 from the NIH Guide for Grants and Contracts

Notice NOT-DC-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-064 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-054 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-22-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) within the Cellular Senescence Network (SenNet) to build an atlas of cellular senescence in mice. The overarching goal of the SenNet consortium is to identify and functionally characterize, at single-cell resolution, the heterogeneity of senescent cells across multiple human tissues in health and lifespan. A previous FOA (RFA-RM-21-008) established the TMCs to generate data and build maps in humans. The purpose of this FOA is to solicit applications that complement the human effort by generating an atlas of cell senescence in mice that will help inform the ongoing effort in humans and serve as a blueprint for future translational research performed in mice. Through collaborative efforts, the murine component of the consortium will generate a multimodal, multidimensional atlas of senescent cells in various murine tissues (tissue choices will be predominantly dictated by the corresponding human tissues already in use within the SenNet consortium); develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable atlas of murine Cellular Senescence. The TMCs solicited through this RFA will create high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the murine lifespan, to generate a murine-specific companion to the human Senescence atlas. The mouse component of the SenNet consortium will initially focus on healthy murine tissues (modified disease models are not allowed) derived from both inbred and outbred mouse strains that are commonly used and have demonstrated value in pre-clinical research. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ-, tissue- and single-cell- level using omics, imaging and other approaches,

Funding Opportunity RFA-HD-22-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants.

Funding Opportunity RFA-AT-22-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for continuation of a Coordinating Center to provide national leadership for the NIH Health Care Systems (HCS) Research Collaboratory program. The Coordinating Center will 1) further develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research studies in partnership with health care systems; 2) work collaboratively with each Demonstration Project team supported through the Collaboratory program, including their partnering HCS, to develop, test, and implement the proposed Demonstration Projects while providing technical, design, and coordination support; 3) learn and disseminate the best strategies for engaging HCS as research partners to improve health and care delivery, with a particular focus on HCS with less historical involvement in research studies; and 4) learn, develop, and disseminate the best means of conducting pragmatic clinical trials in HCS to improve the scientific communitys ability to perform future pragmatic trials in a variety of healthcare contexts. The Coordinating Center will also serve as the central resource for the activities of the NIH HCS Research Collaboratory.

Notice NOT-OD-22-015 from the NIH Guide for Grants and Contracts